玛巴洛沙韦:首个靶向于Cap-依赖性核酸内切酶的抗流感药物

Baloxavir marboxil:the first anti-influenza drug targeting Cap-dependent endonuclease

玛巴洛沙韦是首个Cap-依赖性内切酶抑制剂,通过抑制流感病毒RNA聚合酶酸性蛋白亚基内切酶活性,从而抑制流感病毒的复制。玛巴洛沙韦于2022年8月通过美国食品药品监督管理局(FDA)审批,在临床上用于治疗5岁及以上、流感症状不超过48 h的急性无并发症流感患者,并于2023年3月获得中国国家药品监督管理局正式批准。临床试验表明,玛巴洛沙韦具有单剂量给药、安全性高等优势,将成为儿童流感患者的替代药物。

Baloxavir marboxil is the first Cap-dependent endonuclease inhibitor,which inhibits the replication of influenza virus by inhibiting the activity of influenza RNA polymerase acidic protein subunit endonuclease.It was approved by the U.S.Food and Drug Administration in August 2022 for acute uncomplicated influenza patients aged 5 years and older with symptoms less than 48 hours.It was officially approved by the National Medical Products Administration of China in March 2023.Clinical trials have shown that baloxavir marboxil,with its advantages of single dose administration and high safety,may become an alternative for drug-resistant pediatric patients.